What is the recommended dosing schedule for Maxitrol (dexamethasone/neomycin/polymyxin B) ophthalmic suspension in adults and in children aged 2 years and older?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maxitrol Dosing

Administer Maxitrol (dexamethasone 0.1%/neomycin/polymyxin B) ophthalmic suspension 1–2 drops into each affected eye every 3–4 hours initially, with frequency adjusted based on severity; standard maintenance dosing is four times daily. 1, 2

Standard Dosing Regimen

  • Initial dosing: Instill 1–2 drops into the affected eye(s) every 3–4 hours depending on severity of inflammation 2
  • Maintenance dosing: Four times daily once acute inflammation is controlled 1, 3
  • Treatment duration: Guided by clinical response, typically ranging from a few days for acute conjunctivitis to several weeks for chronic blepharitis 1
  • Pediatric dosing: The same dosing schedule applies to children aged 2 years and older as in adults 1
  • For pediatric bacterial conjunctivitis specifically, a four-times-daily regimen for 5–7 days is typical 1

Critical Prescribing Limits

  • Initial prescription should not exceed 20 mL, and renewal requires physician re-examination with magnification (slit lamp biomicroscopy) and fluorescein staining when appropriate 4
  • Re-evaluate after 2 days if signs and symptoms fail to improve 4
  • Children can resume school after 24 hours of treatment initiation when symptoms begin improving 1

Absolute Contraindications

Never use Maxitrol in the following situations:

  • Bacterial keratitis or corneal ulceration as monotherapy – requires immediate ophthalmology referral and fortified antibiotics instead 1, 4
  • Viral ocular diseases including epithelial herpes simplex keratitis, vaccinia, and varicella 1
  • Mycobacterial or fungal eye infections 1
  • Active epithelial defects – preservatives in the formulation worsen epithelial damage 1, 3
  • Contact lens wearers with bacterial conjunctivitis – higher complication risk requiring specialist referral 1

Duration-Based Safety Considerations

  • If therapy extends beyond 8 weeks, switch to loteprednol etabonate 0.5%/tobramycin 0.3% (Zylet), which carries lower risk of intraocular pressure elevation and cataract progression 1, 3
  • Monitor intraocular pressure (IOP) if treatment continues for 10 days or longer 4
  • Dexamethasone carries significant risk of steroid-induced glaucoma with prolonged use 1

Monitoring Requirements

  • Baseline and periodic IOP measurement is essential during corticosteroid therapy 5
  • Pupillary dilation should be performed periodically to evaluate for cataract formation 5
  • Fungal cultures should be obtained if persistent corneal ulceration develops, as fungal infections are prone to develop with long-term corticosteroid use 4

Antibiotic Resistance Prevention

  • Rotate antibiotic formulations intermittently using agents with different mechanisms of action to reduce emergence of resistant organisms 1, 3
  • Avoid chronic prophylactic use without clear indication, as this promotes resistant organisms including methicillin-resistant Staphylococcus aureus 1, 3
  • Prolonged topical antibacterial use may lead to overgrowth of nonsusceptible organisms including fungi 4

Immediate Referral Criteria

Refer to ophthalmology immediately for:

  • Severe or moderate-to-severe pain 1
  • Lack of clinical response after 3–4 days of therapy 1
  • Severe purulent discharge 1
  • Contact lens wearers with bacterial conjunctivitis 1
  • Any suspicion of bacterial keratitis or corneal ulceration 5, 1

Common Pitfalls to Avoid

  • Never combine Maxitrol with eye patching, especially in contact lens wearers, due to increased bacterial keratitis risk 1, 3
  • Do not continue treatment beyond 2 weeks without reassessment and consideration of alternative diagnoses or resistant pathogens 1
  • Do not use preserved formulations when epithelial defects are present 1, 3
  • Vision may be temporarily blurred following administration; patients should exercise caution when operating machinery or driving 4

Administration Technique

  • Avoid touching the bottle tip to eyelids or any surface to prevent contamination 4
  • Keep bottle tightly closed when not in use 4
  • Shake well before using 2
  • Store at 20°–25°C (68°–77°F) 2

References

Guideline

Maxitrol Dosing, Safety, and Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Tobradex Eye Drops Dosage Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.